Baxter International Inc. said it will pay at least $170 million to buy a specialty drug maker that has high hopes for a heart drug used in hospitals to treat irregular heart beats. Get the full story »
Inside these posts: Nexterone
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
